Human Immunodeficiency Virus Pre-Exposure Prophylaxis: Use of Emtricitabine/Tenofovir Alafenamide

被引：3
作者：
Blackwell, Christopher W. [1 ]
Castillo, Humberto Lopez [2 ]
机构：
[1] Univ Cent Florida, Adult Gerontol Acute Care Nurse Practitioner Prog, Coll Nursing, Orlando, FL 32816 USA
[2] Univ Cent Florida, Dept Hlth Sci, Coll Hlth Profess & Sci, Coll Med, Orlando, FL 32816 USA
来源：
JNP-JOURNAL FOR NURSE PRACTITIONERS | 2021年 / 17卷 / 06期
关键词：
AIDS; emtricitabine; tenofovir alafenamide; human immunodeficiency virus; human immunodeficiency virus prevention; pre-exposure prophylaxis; PREVENTING HIV;
D O I：
10.1016/j.nurpra.2021.01.002
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Pre-exposure prophylaxis (PrEP) involves the use of antiretroviral medication in concert with safer sex practices to significantly reduce the risk of type 1 human immunodeficiency virus infection. In October 2019, daily use of emtricitabine/tenofovir alafenamide (FTC/TAF) 200 mg/25 mg was approved as a newer agent for PrEP to prevent HIV-1 infection in at-risk adults and adolescents. The purpose of this article is to: 1) provide an overview of the FTC/TAF regimen and its safety and efficacy profiles, 2) discuss indications and contra-indications of FTC/TAF as PrEP, 3) provide a focused comparison of FTC/TDF with FTC/TAF, and 4) examine issues surrounding cost and accessibility in the United States. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码：673 / 676
页数：4
相关论文
共 15 条
  • [1] Preventing HIV Infection in High-Risk Adolescents Using Preexposure Prophylaxis (PrEP)
    Blackwell, Christopher W.
    [J]. JANAC-JOURNAL OF THE ASSOCIATION OF NURSES IN AIDS CARE, 2018, 29 (05): : 770 - 774
  • [2] Blackwell Christopher W, 2014, Nurse Pract, V39, P50, DOI 10.1097/01.NPR.0000452976.92052.fa
  • [3] Men Who Have Sex With Men and Recruit Bareback Sex Partners on the Internet: Implications for STI and HIV Prevention and Client Education
    Blackwell, Christopher W.
    [J]. AMERICAN JOURNAL OF MENS HEALTH, 2008, 2 (04) : 306 - 313
  • [4] Campbell T, 2019, OPEN FORM INFECT DIS, V6, pPS64
  • [5] Gilead, 701 GIL
  • [6] Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine
    Glidden, David, V
    Mulligan, Kathleen
    McMahan, Vanessa
    Anderson, Peter L.
    Guanira, Juan
    Chariyalertsak, Suwat
    Buchbinder, Susan P.
    Bekker, Linda-Gail
    Schechter, Mauro
    Grinsztejn, Beatriz
    Grant, Robert M.
    [J]. CLINICAL INFECTIOUS DISEASES, 2018, 67 (03) : 411 - 419
  • [7] GSI, 225 GSI
  • [8] Hosek S, 2019, OPEN FORM INFECT DIS, V6, pPS64
  • [9] Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis
    Markowitz, Martin
    Grossman, Howard
    Anderson, Peter L.
    Grant, Robert
    Gandhi, Monica
    Horng, Howard
    Mohri, Hiroshi
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 76 (04) : E104 - E106
  • [10] Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial
    McCormack, Sheena
    Dunn, David T.
    Desai, Monica
    Dolling, David I.
    Gafos, Mitzy
    Gilson, Richard
    Sullivan, Ann K.
    Clarke, Amanda
    Reeves, Iain
    Schembri, Gabriel
    Mackie, Nicola
    Bowman, Christine
    Lacey, Charles J.
    Apea, Vanessa
    Brady, Michael
    Fox, Julie
    Taylor, Stephen
    Antonucci, Simone
    Khoo, Saye H.
    Rooney, James
    Nardone, Anthony
    Fisher, Martin
    McOwan, Alan
    Phillips, Andrew N.
    Johnson, Anne M.
    Gazzard, Brian
    Gill, Owen N.
    [J]. LANCET, 2016, 387 (10013) : 53 - 60
12